Scott Powers

List of Publications by Year
in descending order

13 papers	**1,108** citations	1040056 **9** h-index	1125743 **13** g-index
13 all docs	**13** docs citations	**13** times ranked	**2714** citing authors

#	Article	IF	Citations
1	Identification of a Therapeutic Strategy Targeting Amplified FGF19 in Liver Cancer by Oncogenomic Screening. Cancer Cell, 2011, 19, 347-358.	16.8	379
2	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	30.7	242
3	Oncogenic Myc Induces Expression of Glutamine Synthetase through Promoter Demethylation. Cell Metabolism, 2015, 22, 1068-1077.	16.2	189
4	KRAS drives immune evasion in a genetic model of pancreatic cancer. Nature Communications, 2021, 12, 1482.	12.8	105
5	The DNA Damage Transducer RNF8 Facilitates Cancer Chemoresistance and Progression through Twist Activation. Molecular Cell, 2016, 63, 1021-1033.	9.7	82
6	A systematic evaluation of nucleotide properties for CRISPR sgRNA design. BMC Bioinformatics, 2017, 18, 297.	2.6	29
7	Challenges in Ras therapeutics in pancreatic cancer. Seminars in Cancer Biology, 2019, 54, 101-108.	9.6	29
8	Identification of targetable BRAF Î"N486_P490 variant by whole-genome sequencing leading to dabrafenib-induced remission of a <i>BRAF</i>-mutant pancreatic adenocarcinoma. Journal of Physical Education and Sports Management, 2019, 5, a004424.	1.2	21
9	Comparative single-cell RNA sequencing (scRNA-seq) reveals liver metastasisâ€"specific targets in a patient with small intestinal neuroendocrine cancer. Journal of Physical Education and Sports Management, 2020, 6, a004978.	1.2	12
10	Combinatorial CRISPR/Cas9 Screening Reveals Epistatic Networks of Interacting Tumor Suppressor Genes and Therapeutic Targets in Human Breast Cancer. Cancer Research, 2021, 81, 6090-6105.	0.9	12
11	Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas. Scientific Reports, 2016, 6, 27891.	3.3	4
12	Tandem Duplications May Supply the Missing Genetic Alterations in Many Triple-Negative Breast and Gynecological Cancers. Cancer Cell, 2018, 34, 179-180.	16.8	3
13	Functionally Assessing Candidate Drivers Advances Precision Cancer Medicine. Cancer Cell, 2016, 30, 187-189.	16.8	1